Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23981544 | 1.00 | LTA4H (0.50) | LTA4HBLMACE2GABRR1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7903228 | 0.98 | LTA4H (0.48) | LTA4HBLMACE2GABRR1CYP1A2 | |
| SCHEMBL14611115 | 0.98 | ACE2 (0.50) | LTA4HBLMACE2GABRR1CYP1A2 | |
| SCHEMBL19257888 | 0.93 | BLM (0.52) | LTA4HBLMACE2GABRR1CYP1A2 | |
| SCHEMBL23551728 | 0.93 | BLM (0.52) | LTA4HBLMACE2GABRR1CYP1A2 | |
| SCHEMBL22134234 | 0.84 | — | — | |
| SCHEMBL7179523 | 0.83 | BLM (0.65) | LTA4HBLMACE2GABRR1CYP1A2 | |
| SCHEMBL16330413 | 0.83 | BLM (0.65) | LTA4HBLMACE2GABRR1CYP1A2 | |
| SCHEMBL13082172 | 0.83 | KISS1R (0.53) | LTA4HBLMACE2KISS1RCPB2 | |
| SCHEMBL14525120 | 0.83 | KISS1R (0.53) | LTA4HBLMACE2KISS1RCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2525834-B1 | GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY | NOVO NORDISK HEALTHCARE AG (CH) | 2019-07-17 | — | — | EP | disclosed |
| US-20170283552-A1 | METHODS FOR PREPARING POLYMERIC REAGENTS AND COMPOSITIONS OF POLYMERIC REAGENTS | NEKTAR THERAPEUTICS | 2017-10-05 | — | — | US | disclosed |
| US-9732189-B2 | Methods for preparing polymeric reagents and compositions of polymeric reagents | NEKTAR THERAPEUTICS (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160289382-A1 | METHODS FOR PREPARING POLYMERIC REAGENTS AND COMPOSITIONS OF POLYMERIC REAGENTS | NEKTAR THERAPEUTICS | 2016-10-06 | — | — | US | disclosed |
| US-9334364-B2 | Methods for preparing polymeric reagents and compositions of polymeric reagents | NEKTAR THERAPEUTICS (US) | 2016-05-10 | — | — | US | disclosed |
| US-20140323742-A1 | METHODS FOR PREPARING POLYMERIC REAGENTS AND COMPOSITIONS OF POLYMERIC REAGENTS | NEKTAR THERAPEUTICS | 2014-10-30 | — | — | US | disclosed |
| US-8809489-B2 | Methods for preparing polymeric reagents and compositions of polymeric reagents | NEKTAR THERAPEUTICS (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130253203-A1 | Methods for Preparing Polymeric Reagents and Compositions of Polymeric Reagents | NEKTAR THERAPEUTICS (US) | 2013-09-26 | — | — | US | disclosed |
| US-8461295-B2 | Methods for preparing polymeric reagents and compositions of polymeric reagents | NEKTAR THERAPEUTICS (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120214952-A1 | Methods for Preparing Polymeric Reagents and Compositions of Polymeric Reagents | NEKTAR THERAPEUTICS (US) | 2012-08-23 | — | — | US | disclosed |
| US-8193306-B2 | Methods for preparing polymeric reagents and compositions of polymeric reagents | NEKTAR THERAPEUTICS (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110052674-A1 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20100256310-A1 | Methods for Preparing Polymeric Reagents and Compositions of Polymeric Reagents | NEKTAR THERAPEUTICS (US) | 2010-10-07 | — | — | US | disclosed |
| US-7767784-B2 | Active carbonate esters of water-soluble polyoxyethylene glycol | NEKTAR THERAPEUTICS (US) | 2010-08-03 | — | — | US | disclosed |
| US-20080064851-A1 | Active carbonate esters of water-soluble polyoxyethylene glycol | NEKTAR THERAPEUTICS | 2008-03-13 | — | — | US | disclosed |
| US-7205385-B2 | magnetic resonance imaging agents; poly(amino acid-imaging agent) product can be obtained in high purity without a rigorous purification since all impurities are removed at the monomer synthesis stage | GENERAL ELECTRIC COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052674-A1 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | AGTR1, AGTR2, AGT | LTA4H 1339/4885BLM 4039/4885ACE2 8/4885 |
| US-20130253203-A1 | Methods for Preparing Polymeric Reagents and Compositions of Polymeric Reagents | SI, PHYKPL, PHOSPHO1 | LTA4H 521/4885BLM 1012/4885ACE2 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.